No Data
No Data
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines (BPMC) Gets a Hold From Barclays
Baird Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Raises Target Price to $135
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $125 to $155
Express News | Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target